SOUTH SAN FRANCISCO, Calif., March 18, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) will announce its fourth quarter and full year 2008 results on Tuesday, March 31, 2009, after the close of the financial markets. Following the announcement, Hana Biosciences' management team will host a conference call that day at 5:00pm ET, 2:00pm PT to discuss results and highlights of the fourth quarter and full year 2008 and a business update.
Conference call details:
Date: Tuesday, March 31, 2009 Time: 5:00pm ET, 2:00pm PT Dial-in (U.S. and Canada): (877) 407-8031 Dial-in (International): (201) 689-8031 Webcast: www.hanabiosciences.com
A replay of this call will be available for one week by dialing (877) 660-6853 U.S./Canada and (201) 612-7415 for international participants. When prompted, enter Account Number #286 and Conference ID #317545. An archived version of the webcast will also be available via the company's website for 14 days following the call.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. (Nasdaq:HNAB) is a biopharmaceutical company dedicated to developing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company has two lead product candidates that target large markets and are in pivotal and/or proof-of-concept clinical trials. Marqibo is being developed to treat lymphoid cancers such as acute lymphoblastic leukemia and lymphomas. Menadione topical lotion is a first-in-class compound being developed as a prevention and/or treatment of skin toxicity associated with epidermal growth factor receptor inhibitors like Erbitux(r) and Tarceva(r). The Company has additional pipeline opportunities that, like Marqibo, improve delivery and enhance the therapeutic index of well characterized, proven chemotherapies. Further information on Hana Biosciences can be found at www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290